# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-239417
Filing Date
2026-05-26
Accepted
2026-05-26 16:29:25
Documents
71
Period of Report
2026-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | ck0002096997-20260331.htm iXBRL | 10-Q | 2601251
2 | EX-31.1 | ck0002096997-ex31_1.htm | EX-31.1 | 16964
3 | EX-31.2 | ck0002096997-ex31_2.htm | EX-31.2 | 17263
4 | EX-32.1 | ck0002096997-ex32_1.htm | EX-32.1 | 9845
5 | EX-32.2 | ck0002096997-ex32_2.htm | EX-32.2 | 9911
6 | GRAPHIC | img226874799_0.jpg | GRAPHIC | 99559
| Complete submission text file | 0001193125-26-239417.txt |  | 9589582

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
7 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | ck0002096997-20260331.xsd | EX-101.SCH | 941300
75 | EXTRACTED XBRL INSTANCE DOCUMENT | ck0002096997-20260331_htm.xml | XML | 1794429

Mailing Address 180 THIRD AVENUE 4TH FLOOR WALTHAM MA 02451
Business Address 180 THIRD AVENUE 4TH FLOOR WALTHAM MA 02451 508-440-9475
Kailera Therapeutics, Inc. (Filer) CIK: 0002096997 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-43233 | Film No.: 261020337
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)